Status:
COMPLETED
Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin
Lead Sponsor:
Boehringer Ingelheim
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
This protocol is for a series of comparative effectiveness and safety analyses within periodically updated cohorts of patients initiating linagliptin, other DPP-4 inhibitors, and other oral hypoglycem...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- A dispensing of an oral hypoglycemic medication
- A diagnosis of type 2 diabetes mellitus (T2DM)
- Exclusion criteria:
- less than 18 years old
- missing or ambiguous age or sex information
- at least one diagnosis of type 1 diabetes mellitus
- less than 6 months enrolment in the database preceding the date of the first dispensing
- secondary diabetes
- history of cancer
- end-stage renal disease (ESRD)
- HIV
- organ transplant
Exclusion
Key Trial Info
Start Date :
July 30 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 26 2019
Estimated Enrollment :
189426 Patients enrolled
Trial Details
Trial ID
NCT02197078
Start Date
July 30 2014
End Date
February 26 2019
Last Update
April 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02120